The 3rd EURL-AR proficiency test on selective isolation of e. coli with presumptive esbl or ampc phenotypes from meat or caecal samples - 2017 by Kjeldgaard, Jette Sejer et al.
 
 
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright 
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
 Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
 You may not further distribute the material or use it for any profit-making activity or commercial gain 
 You may freely distribute the URL identifying the publication in the public portal 
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
  
 
   
 
 
Downloaded from orbit.dtu.dk on: Mar 30, 2019
The 3rd EURL-AR proficiency test on selective isolation of e. coli with presumptive
esbl or ampc phenotypes from meat or caecal samples - 2017
Kjeldgaard, Jette Sejer; Karlsmose Pedersen, Susanne; Hendriksen, Rene S.; Bortolaia, Valeria
Publication date:
2018
Document Version
Publisher's PDF, also known as Version of record
Link back to DTU Orbit
Citation (APA):
Kjeldgaard, J. S., Karlsmose Pedersen, S., Hendriksen, R. S., & Bortolaia, V. (2018). The 3rd EURL-AR
proficiency test on selective isolation of e. coli with presumptive esbl or ampc phenotypes from meat or caecal
samples - 2017. Kgs. Lyngby: Technical University of Denmark.
THE 3rd EURL-AR PROFICIENCY TEST ON  SELEC-
TIVE ISOLATION OF E. COLI WITH PRESUMPTIVE 
ESBL OR AMPC PHENOTYPES FROM MEAT OR 
CAECAL SAMPLES - 2017
Jette Sejer Kjeldgaard
Susanne Karlsmose Pedersen
Rene S. Hendriksen
Valeria Bortolaia
  
 
THE 3rd EURL-AR PROFICIENCY TEST ON SELECTIVE ISOLATION OF ESCHERICHIA 
COLI WITH PRESUMPTIVE ESBL OR AMPC PHENOTYPES FROM MEAT AND CAECAL 
SAMPLES - 2017 
 
 
December 2018 
Copyright: National Food Institute, Technical University of Denmark 
Photo: Lina Cavaco 
ISBN: 978-87-93565-35-7 
 
This report is available at 
www.food.dtu.dk 
 
National Food Institute 
Technical University of Denmark 
Kemitorvet 
Building 202 
DK-2800 Kgs.Lyngby 
Tel:  +45 35 88 70 00 
Fax: +45 35 88 70 01 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                    
3 
Index 
Index ........................................................................................................................................................... 3 
1. Introduction ............................................................................................................................................. 4 
2. Materials and Methods ........................................................................................................................... 5 
2.1 Participants in EQAS 2017 .............................................................................................................. 5 
2.2 Preparation of samples .................................................................................................................... 5 
2.3 Isolation and identification of ESBL, AmpC or carbapenemase producing E. coli from meat and 
caecal samples ....................................................................................................................................... 7 
2.4 Antimicrobial susceptibility testing.................................................................................................... 7 
2.5 Distribution ....................................................................................................................................... 7 
2.6 Procedure ......................................................................................................................................... 8 
3. Results .................................................................................................................................................... 9 
3.1 Data omitted from the report ............................................................................................................ 9 
3.2 Methods used by EQAS-participants ............................................................................................. 10 
3.3 ESBL /AmpC and carbapenemase producing E. coli isolation and identification .......................... 11 
3.4 Antimicrobial susceptibility testing................................................................................................... 11 
3.5 ESBL/AmpC phenotypic testing conclusions ................................................................................. 13 
4. Discussion ............................................................................................................................................ 14 
4.1 ESBL and AmpC and carbapenemase-producing E. coli isolation and identification ................... 14 
4.2 Antimicrobial susceptibility testing.................................................................................................. 14 
4.3 ESBL /AmpC phenotypic testing conclusions ................................................................................ 14 
5. Conclusion ............................................................................................................................................ 15 
6. References ........................................................................................................................................... 15 
 
Appendix 1. Pre-notification EURL-AR EQAS matrix 2017 
Appendix 2. List of participants 
Appendix 3. Expected results  
Appendix 4. Protocol EQAS matrix 2017 
Appendix 5. Examples of Test forms EQAS matrix 2017  
                                                                                                    
4 
1. Introduction 
This report describes and summarises results 
from the third matrix-based proficiency test 
conducted by The National Food Institute (DTU 
Food) as the EU Reference Laboratory for 
Antimicrobial Resistance (EURL-AR) as an 
External Quality Assurance System (EQAS). 
This proficiency test focuses on selective 
isolation of extended spectrum beta-lactamase 
(ESBL) and AmpC-producing E. coli from meat 
and caecal samples of animal origin and 
antimicrobial susceptibility testing (AST) of the 
isolated E. coli. In addition, the proficiency test 
includes optional isolation of carbapenemases 
and OXA-48-producing E. coli.  
Extended spectrum beta-lactamase (ESBL) and 
AmpC-producing E. coli continue to spread in 
food producing animals. In 2013, the European 
Commission (EC) decided to include the 
isolation of ESBL and AmpC-producing E. coli 
as mandatory parts of the EU monitoring and 
this started during 2015. The screening 
includes matrix samples consisting of either 
meat or caecal samples of animal origin in the 
EU Member States (MS) and affiliated countries 
according to a common protocol defined by the 
EC and validated by the EURL-AR (EURL-AR, 
2017).  
In 2016 the EQAS was extended also to include 
carbapenemase and/or OXA-48-producing E. 
coli, thereby including the optional isolation of 
these using the EURL-AR selective isolation 
protocol on agar plates suitable for isolation of 
carbapenemase-producing E. coli (EURL-AR, 
2017).   
Similar to the previous EURL-AR matrix based 
EQAS’, the aim of this specific EQAS was to i) 
monitor the capacity of the National Reference 
Laboratories (NRL-AR) for isolation, 
identification and AST of ESBL/AmpC or 
carbapenemase-producing E. coli, ii) identify 
laboratories which may need assistance to 
improve their performance in isolation and AST 
of E. coli from matrices, and iii) identify potential 
problems or focus areas for future training and 
research. 
From January 2016, the laboratories should 
have implemented the methods and have 
started the monitoring on meat and caecal 
samples of poultry origin. The participation in 
this EQAS may be used to assess 
retrospectively the quality of data provided to 
the European Food Safety Agency (EFSA).  
In reading this report, the following important 
considerations should be taken into account:  
1) Expected results were generated by 
performing Minimum Inhibitory Concentration 
(MIC) determination for all test strains prior to 
selection of strains and MIC’s were confirmed 
upon selection of strains at the Technical 
University of Denmark, National Food Institute 
(DTU Food). The genetic basis for resistance 
was known, as all the selected test strains had 
been whole-genome sequenced (WGS). The 
MIC determination was repeated after 
preparation of the matrix samples of meat and 
caecal, which revealed a risk for deviating 
phenotypic results (See section 3.1).  
2) No thresholds have been set in advance to 
evaluate the acceptance of the performance of 
the participating laboratories and therefore the 
results will not be classified as above or below 
a threshold, but evaluated case by case.  
3) Evaluation of a result as ‘deviating from the 
expected interpretation’ should be carefully 
analysed in a self-evaluation performed by the 
participant, including considerations of 
corrective actions in the laboratory. Note that 
since methods used for MIC determination has 
limitations, it is not considered a mistake to 
obtain a one-fold dilution difference in the MIC 
of a specific antimicrobial when testing the 
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same strains. If, however, the expected MIC is 
close to the breakpoint value for categorising 
the strain as susceptible or resistant, one two-
fold dilution difference (which is acceptable) 
may result in two different interpretations, i.e. 
the same strain can be categorized as 
susceptible and resistant. This result will be 
evaluated as correct in one case, but incorrect 
when the evaluation is based on AST 
interpretations. In the organization of the EQAS, 
we try to avoid these situations by choosing test 
strains with MIC values distant from the cut-offs 
for resistance, which is not always feasible for 
all strains and all antimicrobials. Therefore, the 
EURL-AR network unanimously established in 
2008 that if there are less than 75% correct 
results for a specific strain/antimicrobial 
combination, the reasons for this situation must 
be further examined and, on selected occasions 
explained in details case by case, these results 
may subsequently be omitted from the 
evaluation report.  
The data in this report is presented with 
laboratory codes. A laboratory code is known 
only by the individual laboratory, whereas the 
entire list of laboratories and their codes is 
confidential and known only by relevant 
representatives of the EURL-AR and the EU 
Commission. All conclusions are public.  
This third matrix EQAS was organized by the 
EURL-AR at the National Food Institute (DTU 
Food), Kgs. Lyngby, Denmark. The report is 
approved in its final version by a technical 
advisory group composed by competent 
representatives from all NRL-ARs, who meets 
annually at the EURL-AR workshop.  
 
2. Materials and Methods  
2.1 Participants in EQAS 2017 
A pre-notification (App. 1), announcing the 
matrix EQAS 2017, was distributed on the 3rd of 
August 2017 by e-mail to the designated NRLs 
including all EU countries and Iceland, Norway 
and Switzerland. In total 35 laboratories 
participated in the matrix EQAS (App. 2) 
involving one NRL from each of the 28 MS (two 
from two countries, analysing meat and caecal 
sample in different laboratories), and from 
Iceland, Norway and Switzerland, plus 
additional laboratories. As results from only one 
laboratory per country are included in this 
report, 33 laboratory results from 31 countries 
are described. The exception was the two 
countries, who has different laboratories 
enrolled for handling meat and caecal samples, 
and therefore had two different NRLs enrolled.  
Furthermore, one additional laboratory from 
each of the Netherlands, Spain and United 
Kingdom participated. These were invited 
based on their participation in previous EQAS 
iterations and/or affiliation to the EU network 
and provided results but were not included 
further in the report. Participants from non-EU 
MS were charged a fee for participation 
whereas participation was free of charge for EU 
MS, but each laboratory was expected to cover 
expenses associated with the analyses. The 
European countries participating are marked on 
map in Figure 1. 
2.2 Preparation of samples  
Eight samples were prepared and dispatched 
for isolation of ESBL, AmpC or carba-
penemase-producing E. coli, including 
identification, and antimicrobial susceptibility 
testing (AST) of the obtained isolates. The 
samples included five bovine meat and three 
pig caecal samples and were either prepared 
by spiking with test strains or unmodified.  
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Figure 1 Countries participating in matrix EQAS 2017 
 
The meat used to prepare the samples was 
minced beef meat of Danish origin (born, 
raised, slaughtered and packed in Denmark) 
acquired in local supermarkets (at least three 
batches were bought in sufficient amount for 
covering both the pre-tests and preparation of 
the samples). The meat was pretested using 
the official method for selective isolation of E. 
coli producing ESBL, AmpC or carbapenemase 
to ensure the batch used was negative for 
those and contained some background flora. A 
batch fulfilling these criteria was chosen for 
preparation of aliquots of 25 g of meat that were 
either used directly as blank samples or spiked 
as follows. 
The test isolates used in the spiking of meat 
samples within the EQAS matrix 2017 were 
prepared in advance and sub-cultured the day 
before sample preparation. For the sample 
preparation and standardization of the spiking, 
suspensions equal to McFarland 0.5 were 
prepared in saline tubes with the relevant 
isolates to contain about 108 CFU/mL, as 
confirmed by viable counts of serial dilutions on 
Luria Bertani (LB) agar plates. The 
standardized suspensions were further diluted 
in ten-fold dilutions and the meat samples (25 
g) were spiked with 25 µl of the chosen 
dilutions. The spiking dilutions were chosen 
based on the results obtained in the previous 
matrix EQAS 2016 and a prior pilot test. The 
final inoculum found in the samples in this 
EQAS was expected to be approx. 103 CFU/g 
meat, for the samples EURL-M-3.2, M-3.3, M-
3.4 and M-3.5, whereas the sample M-3.1 was 
spiked with a lower amount of about 100 CFU/g 
meat of the test strain. The sample M-3.2 was 
spiked as mentioned above, however with a 
susceptible E. coli strain (ATCC 25922) and 
therefore expected to be negative. 
For the caecal samples, previous testing 
showed instability of ESBL E. coli inoculum in 
pig caecal (matrix EQAS 2015), thus a pilot test 
was initially conducted. The pilot aimed both to 
ensure that we could obtain ESBL-negative 
caecal material, but also to identify ESBL/AmpC 
producing E. coli isolates capable of surviving 
as inoculum in the caecal samples, in the 
period needed to ship and analyse samples. 
One slaughterhouse provided on Oct. 2nd ten 
pig caecal samples from different herds. These 
samples were tested individually using the 
official selective isolation protocol for ESBL, 
AmpC and carbapenemase-producing E. coli.  
Two of the caecal samples were found to 
contain presumptive ESBL producing E. coli, 
and these isolates were included in the stability 
test, together with five E. coli from the EURL-
AR strain collection, originally deriving from pig 
caecal. One ESBL-negative caecal batch was 
chosen for individual inoculation of a total of 
seven test strains (10 µl inoculum in 1 g caecal 
sample for a final inoculum of approx. 104 
CFU/g), and their viability was evaluated  in up 
to ten days. Two ESBL-producing E. coli were 
chosen as the final test strains.  
On Oct. 30th, additional 10 pig caecal samples 
were obtained at one slaughterhouse, for the 
final preparation of the matrix samples.  These 
samples were likewise tested individually for 
natural occurrence of ESBL, AmpC and 
carbapenemase-producing E. coli. One 
negative caecal batch was chosen for 
preparation of the matrix caecal samples for the 
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EQAS. Thereby 1 g aliquots of caecal content 
was spiked with 10 µl of a dilution containing 
106 CFU/ml, causing an expected spiking level 
of 104 CFU/g for the samples M-3.6 and M-3.7, 
while sample M-3.8 was kept as blank. 
The minimal inhibitory concentrations (MIC) of 
selected antimicrobials were determined using 
broth microdilution method both for the strains 
used for spiking during the preparation work 
and for the isolates obtained in the 
homogeneity testing after sample preparation to 
generate expected results (App. 3). 
For follow-up on the stability of the inoculum in 
the matrix samples after shipping, repeated 
testing was performed on sets the eight 
samples in four time points after shipment 
(during two weeks). In this period the meat and 
caecal samples were kept at 4°C, to mimic the 
conditions in the shipment parcel. 
 
2.3 Isolation and identification of 
ESBL, AmpC or carbapenemase 
producing E. coli from meat and 
caecal samples  
The official protocols for selective isolation and 
identification of the ESBL, AmpC and/or 
carbapenemase-producing E. coli isolates 
contained in the samples were available on the 
EURL website, http://www.eurl-ar.eu (App. 4). 
For the confirmation of E. coli isolates, different 
methods were allowed as these are not 
specified in the legislation (EU Commission 
implementing decision on the monitoring and 
reporting antimicrobial resistance in zoonotic 
and commensal bacteria 2013/652/EU). The 
description of the method used for selective 
isolation of presumptive ESBL, AmpC or 
carbapenemase-producing E. coli as well as 
species identification was requested as part of 
the methods sheet to be completed in the 
database upload system. 
2.4 Antimicrobial susceptibility 
testing 
The panels of antimicrobials recommended for 
AST in this proficiency test are those included 
in the EU Commission implementing decision 
on the monitoring and reporting Antimicrobial 
resistance in zoonotic and commensal bacteria 
2013/652/EU (Table 1). 
Guidelines for performing the antimicrobial 
susceptibility testing using dilution methods 
were set according to the Clinical and 
Laboratory Standards Institute (CLSI) document 
– M7-A10 (2015) “Methods for Dilution 
Antimicrobial Susceptibility Tests for Bacteria 
That Grow Aerobically; Approved Standard - 
tenth Edition”” and whenever commercial 
methods were used, the guidelines of the 
manufacturer were followed.  
MIC results were interpreted by using EUCAST 
epidemiological cut-off values 
(www.eucast.org), as included in the regulation 
referred above or as recommended by EFSA 
and described in the EQAS protocol (App. 4). 
Results of the ESBL confirmatory testing were 
interpreted according to the recommendations 
by EFSA and as referred in the regulation, 
using MIC testing on the second panel of 
antimicrobials, which is intended to be used 
every time a strain is found resistant to either 
cefotaxime, ceftazidime or meropenem.  
2.5 Distribution 
The meat samples were frozen at -80°C and 
kept at this temperature after preparation and 
until the time for shipment. The caecal samples 
were sent shortly after preparation, and 
therefore kept at 4°C until the time for shipment. 
At the day of shipment, the samples were tightly 
packed in thermoboxes with cooling elements, 
frozen at -80°C. The parcels contained the eight 
samples in tubes, and an additional tube 
contained a temperature logger to register the 
temperature at 15 min intervals during 
transport. Furthermore, the parcel contained a 
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welcome letter with the login and password to 
the online database for the data upload and a 
labelled envelope for returning the temperature 
logger to the EURL-AR. 
The protocol for the EQAS and the test forms 
were made available online on the EURL-AR 
website, http://www.eurl-ar.eu before launching 
this EQAS. 
The thermoboxes used for the shipment of 
samples were enclosed in double pack 
containers and sent to the selected laboratories 
according to the International Air Transport 
Association (IATA) regulations as “Biological 
Substance category B” classified UN3373. The 
parcels were dispatched from DTU-Food 
November 6th 2017. 
2.6 Procedure 
The laboratories were instructed to download 
the protocol and test forms (App. 4 and 5), from 
http://www.eurl-ar.eu and to process the 
samples following the EU protocol for selective 
isolation of presumptive ESBL, AmpC and/ 
carbapenemase producing E. coli from either 
meat or caecal samples, precisely as they 
would normally do for the EFSA monitoring. For 
the results collection the NRLs were instructed 
to upload of the data in the web based 
database, which was designed and prepared 
for this EQAS and opened after sample 
shipment and until the deadline. 
After completion of the tests, the laboratories 
were requested to enter the obtained results 
into the electronic sheet in the EURL-AR web 
based database through a secured individual 
login (App 5). The database was activated on 
the 28th of November 2017, and was closed 
December 29th 2017. 
For the first part of the results of the selective 
isolation procedure for ESBL /AmpC and for 
carbapenemases, the results obtained from the 
isolation procedures samples were evaluated 
separately by defining the samples as positive if 
an isolate was obtained and positively identified 
as E. coli. Additionally, the results of 
susceptibility testing of the obtained isolates 
using both MIC panels were analysed 
separately in similar way as to the similarly to 
the E. coli AST EQAS, including the read 
values of MIC and their interpretations. As a 
Table 1. Panel of antimicrobials recommended for susceptibility testing of bacteria included in this EQAS 2017 component 
Escherichia coli 
EUVSEC 
Escherichia coli 
EUVSEC2 
Ampicillin, AMP Cefepime, FEP 
Azithromycin, AZI Cefotaxime + clavulanic acid (F/C) 
Cefotaxime, FOT Cefotaxime, FOT 
Ceftazidime, TAZ Cefoxitin, FOX 
Chloramphenicol, CHL Ceftazidime, TAZ 
Ciprofloxacin, CIP Ceftazidime+ clavulanic acid (T/C) 
Colistin, COL Ertapenem, ETP 
Gentamicin, GEN Imipenem, IMI 
Meropenem, MERO Meropenem, MERO 
Nalidixic acid, NAL Temocillin, TRM 
Sulfamethoxazole, SMX  
Tetracycline, TET  
Tigecycline, TGC  
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conclusion of the susceptibility testing, the 
participants were asked to classify the isolates 
obtained according to the defined EFSA criteria 
for interpretation of ESBL/Ampc and/or 
carbapenemase producing isolates. 
After the deadline, the qualitative results 
indicating if the samples were positive or 
negative for ESBL/AmpC, or carbapenemase-
producing E. coli (OXA-48 and other), as well 
as the interpretations of the susceptibility tests 
results, and the conclusion on the observed E. 
coli phenotypes were evaluated against the 
expected results and scored as correct or 
incorrect. As no threshold is agreed the 
performance was evaluated case by case and 
not classified into acceptable or unacceptable 
based on the deviation percentage.  
3. Results 
Upon arrival of the parcels, the participants 
were requested to provide more information in a 
small introductory questionnaire on the 
database, including details on sample reception 
(measured temperature and date/time), the 
monitoring activities, and the methods used in 
their laboratory. As requested, the participating 
laboratories have, with one exception, returned 
the temperature loggers to the EURL. Here, the 
registration of the temperature was extracted 
and read to provide the temperature ranges 
along the shipment and at sample 
reception/opening. All samples were registered 
to be between -1°C and 2,5°C at arrival inferred 
from the temperature at opening time from the 
temperature logger registration and thereby all 
samples were expected to be in good 
conditions for testing at the time for opening of 
the parcels.  
3.1 Data omitted from the report 
The total number of test results for ESBL/AmpC 
qualitative isolation considered for this report 
was 248 tests. As mentioned in the introduction, 
some deviations in the MIC results were seen 
by the EURL-AR, when the E. coli were re-
isolated from the meat matrix. As the meat and 
caecal matrices have a natural background of 
bacteria from the animal itself and meat also 
from handling and processing, there is a risk for 
presence of E. coli and other 
Enterobacteriaceae. As such the strain M-3.4 
exhibited a different, distinct phenotype in 14 
labs (56%) out of the 25 labs that isolated this 
strain from meat, with analogous deviations in 
AZI, CHL, GEN, TET and TMP. Furthermore, 
other deviations for FEP, FOT, IMI occurred in 
6-19 labs (25-75 %), resulting in omission of all 
tests for M-3.4. As such, the number of test 
results evaluated in this report is 217. The 
deviating phenotype is described in App. 3b. 
 
Likewise, M-3.5 turned out to have a different 
resistance pattern in 27 of 31 countries (87 %), 
showing analogous deviating MIC results for 
CIP, NAL, SMX, TET and TMP. The results for 
these five antibiotics will not be evaluated as 
errors, and the results of this different 
phenotype are included in the table of expected 
resistance in Appendix 3b.   
 
For the strain M-3.3/cefepime the expected 
interpretation was ‘resistant’, however 20 labs 
(67 %) found the strain sensitive to cefepime. 
All deviations were based on MIC values one 
step from the expected, but for this strain the 
MIC was close to the cut-off.   
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3.2 Methods used by EQAS-
participants 
All 33 participating laboratories, which have 
submitted results, participated in the ESBL and 
AmpC isolation and performed the identification 
and susceptibility of the respective isolates. 
Five laboratories reported that they did not 
perform the optional carbapenemases selective 
isolation. The number of qualitative isolation 
tests results reported was variable including 
results for three to eight samples, depending on 
how many samples were tested (a few 
participants only tested meat or caecal sample 
while most others tested both), for the 
antimicrobial susceptibility test it depended on 
how many isolates were found and further 
tested in the MIC panels.  
 
Information on the methods used for isolation, 
identification and typing was collected from the 
participants through the database.  
Most laboratories (n=32) reported that isolation 
had been performed following the exact 
procedures described in the protocol provided 
One lab reported using LB as enrichment 
medium for meat samples only. The species 
identification was performed equally using 
biochemical tests (n=10), MALDI TOF (n=9) or 
chromogenic agar plating (n=9), and PCR using 
specific targets to confirm the ID (n=4). 
Additionally some laboratories reported using 
second and third identification methods as 
supplement.  
  
The broth microdilution testing was performed 
using the antimicrobials and ranges defined 
under the EU Commission regulation 652/2013 
for testing the isolated and identified E. coli 
isolates using panel 1 (EUVSEC). Additional 
AST of the presumptive ESBL/AmpC and/or 
carbapenemase isolates was performed using 
panel 2 (EUVSEC2) if relevant and 
interpretation of the results according to the 
EFSA criteria for ESBL/AmpC and 
carbapenemase phenotypic classification. 
Table 2. The overall performance of ESBL/AmpC isolation and identification, 2017. 
Isolation of ESBL /AMPC from samples  Correctly classified samples 
Number of performed tests Number of correct tests 
N % N % 
217 100 215 99.1 
Number of expected negative tests Number of correctly identified negative tests 
N % N % 
62 29 62 100 
Number of expected positive tests Number of correctly identified positive tests 
N % N % 
155 71 153 98.7 
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3.3 ESBL /AmpC and 
carbapenemase producing E. coli 
isolation and identification 
ESBL/AmpC 
The total amount of test results was 217 tests 
for the ESBL/AmpC isolation qualitative results. 
In this trial, 29 participating NRL’s reported 
results for all the eight samples sent. Two 
laboratories reported only results for the meat 
samples (Labs, #38, and #41) and two 
laboratories reported only results for the caecal 
samples (Labs #32 and #58). All in all 215 tests 
were correct, corresponding to 99.1% of correct 
results. From the 62 samples expected to be 
negative all were correctly assigned. Regarding 
the 155 samples expected to be found positive, 
all but two were correctly found positive. These 
two deviations were observed by Lab #23 that 
determined the meat sample M-3.3 and the 
caecal sample M-3.7 as negative (Table 2). One 
laboratory (#22) measured unexpected high 
MIC for IMI but not for MERO in sample M-3.7, 
and did thereby not have a clear phenotype, 
leading to the classification ‘Other phenotype’. 
Additional two laboratories (#6 and #41) 
reported elevated resistance to FOX in sample 
M-3.1, leading to the classification of ESBL + 
AmpC.  
Other carbapenemases and OXA-48 
The specific isolation of presumptive 
carbapenemase producing E. coli was 
performed by extending the protocol to include 
isolation on CARBA selective agar plates as 
described in the EURL-AR protocols. Five labs 
did not perform the optional carbapenemase 
selective isolation but defined results based on 
the findings with the in the ESBL/ampC 
selective method and AST results.  
The plates used for this purpose were chosen 
by the laboratories as the protocol defines that 
any suitable plates for selective isolation of 
carbapenemase- and OXA-48-producing E. coli 
may be used. Most participants declared the 
use of the chromogenic agar ChromID CARBA 
and ChromID OXA or CARBA Smart 
combination plates (as reported by eight and 
five participants, respectively). A total of 11 
participants did not report the brand of plates 
being used for this purpose, even though they 
report the EURL-AR protocol was followed. As 
the carbapenemase producing isolate in sample 
3.4 ended up with vast deviations in the 
phenotype, this has been excluded from the 
evaluation.   
3.4 Antimicrobial susceptibility 
testing 
A total of 3364 tests results were uploaded, 
excluding the omitted strain M-3.4, and 3332 
(99.0 %) of these were correct. The 33 labs 
uploaded a variable number of results, 
depending on the samples found positive and 
isolates tested in one or both panels, ranging 
from 48 to 119 test results per participant. 
The analysis per laboratory identified twenty-
seven laboratories with no deviations while the 
others had deviation percentages ranging from 
0.9 % to 1.6 %. (Figure 2). As the performance 
on the AST depends on the isolation and 
identification procedures, no threshold was set 
for acceptance as the capacity for performing 
AST of E. coli is analysed more accurately in 
the E. coli AST EQAS. However, the AST 
results have improved compared to the 
ESBL/AmpC EQAS performed in 2016. 
In the analysis of deviations per antimicrobial, it 
was observed that the highest deviation 
percentage was found for cefotaxime (2.6 %) 
followed by cefoxitin and ciprofloxacin (1.3 %) 
(Figure 3). 
The analysis of deviations per sample indicates 
that the highest deviation (3.0%, 20 deviations) 
was observed for sample M-3.3. All other 
samples had deviation levels below 1 % (Figure 
4). 
                                                                                                    
12 
 
Figure 2. Deviations in antimicrobial susceptibility testing per participating laboratory 
 
Figure 3. Number of deviations per antimicrobial in EQAS matrix 2017 (AST results). 
 
Figure 4.  Number of deviations per sample in EQAS matrix 2017 (AST results). 
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3.5 ESBL/AmpC phenotypic testing 
conclusions 
The sample M-3.1 contained ESBL producing 
CTX-M-65 and OXA-1; sample M-3.3 contained 
an isolate expressing AmpC phenotype by 
mutations in the AmpC promoter region; sample 
M-3.4 contained OXA-48, which mediates 
carbapenemase, but not ESBL phenotype. The 
samples M-3.5, M-3.6 and M-3.7 contained 
ESBL expressing isolates, mediated by CTX-M-
32 and TEM-1B (M-3.5), CTX-M-15 (M-3.6) and 
SHV12 and TEM-1B (M-3.7). The remaining 
samples (M-3.2 and M-3.8) did not contain 
ESBL or AmpC presumptive isolates and were 
expected to be negative. The sample M-3.4 
was totally excluded from evaluation due to 
multiple deviations in the phenotype, affecting 
the MIC results of five to eight different 
antibiotics and thereby also the ESBL/AmpC or 
carbapenemase phenotype. For sample M-3.5, 
there will be no evaluation on five antibiotics 
(CIP, NAL, SMX, TET and TMP), albeit not 
affecting the ESBL/AmpC or carbapenemase 
phenotype. 
Hence, of 153 results uploaded and evaluated, 
150 were correct (98.0 %) and three were 
deviating. These three cases included two 
instances of ESBL strain M-3.1 being classified 
as ‘Presumptive ESBL + pAmpC’ (Labs #6 and 
#41) and ESBL strain M-3.7 being classified as 
‘Other phenotype’ (Lab #22).  
Of 153 results uploaded, 150 were correct (98.0 
%) and three were deviating. These three cases 
included two instances of ESBL strain M-3.1 
being classified as ‘Presumptive ESBL + 
pAmpC’ (Labs #6 and #41) and ESBL strain M-
3.7 being classified as ‘Other phenotype’ (Lab 
#22).   
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4. Discussion
4.1 ESBL and AmpC and 
carbapenemase-producing E. coli 
isolation and identification 
The 2017 EURL-AR matrix EQAS trial was the 
third of its kind and it was conducted on 
samples of animal origin similar to those 
produced in the first round of this EQAS in 2015 
(beef meat, pig caecal). Some challenges were 
met for the selection of test strains with abilities 
to survive in pig caecal samples, but choosing 
strains of the same origin proved to be 
beneficial. Thus, the ability of the plasmids 
carrying the relevant resistance genes to 
spread to background microorganisms in the 
matrix samples ended up being problematic, 
despite initial screening of the meat and caecal 
samples. It was specifically problematic for the 
meat samples, as two of the four spiked 
isolates turned out to be of different resistance 
phenotype after passage in meat. As the 
screening only serves to reveal possible 
ESBL/AmpC contamination and a rough 
estimation of the level of background bacteria, it 
is practically impossible to avoid having generic 
Enterobacteriaceae or E. coli in the meat 
matrix. 
This is a great limitation for the matrix EQAS, 
compared to other EQAS’ on pure isolates. In 
general, the ESBL/AmpC isolation was 
successful, despite one lab that did not succeed 
to isolate two of the ESBL strains, one each 
from meat and caecal.  
4.2 Antimicrobial susceptibility 
testing 
The results uploaded were largely marked by 
the challenges to keep the resistance plasmid  
in the intended E. coli background, and the 
expected results were in several cases 
outnumbered by other, distinct resistance 
patterns. Thirty-one results were omitted from 
evaluation, mainly due to these changes. The 
remaining results, however, were generally very 
precise. In 2017, twenty-seven labs had no 
deviations in the evaluated AST results, 
compared to seven labs in 2016. The 
challenges met this year were not completely 
unexpected, as working with isolates in a matrix 
is not unlikely to cause problems in retrieving 
the right isolates from the samples, or changes 
could have occurred in the isolate composition 
in the samples or the isolate characteristics 
(conjugation, or plasmid losses). Some of the 
deviating results were further caused by MIC 
results close to breakpoint, and this should 
carefully be considered when selecting the 
strains for spiking samples. 
4.3 ESBL /AmpC phenotypic testing 
conclusions 
As what regards to the final conclusions for the 
AST testing and phenotypic confirmation, the 
conclusions depends heavily on the isolation 
process, thus some of the deviations might be 
related to the isolation of strains that have 
different characteristics. Thus, the primary AST 
results, used for classification of ESBL, AmpC, 
carbapenemases or other phenotypes were 
generally very good. In two instances, 
unexpected high cefoxitin MIC results led to 
deviating classification of ESBL strains as ESBL 
+ AmpC (M-3.1), and one ESBL strain (M-3.7) 
was mis-classified as other phenotype.  
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5. Conclusion 
In general, the results of this matrix EQAS 
demonstrate that most participating labs have 
well established methods to isolate ESBL and 
AmpC carrying strains from meat or caecal 
samples. One issue that can be commented is 
the amount of false positives in the selective 
isolation of carbapenemase -producing isolates, 
but the labs perform very well in identifying 
these as non-E. coli. There is a need to strictly 
control the media and the procedures of the 
selective isolation to select ESBL and AmpC or 
carbapenemase-producing E. coli and to do 
species identification with reliable methods to 
allow detection of all relevant isolates with 
increased sensitivity. 
The susceptibility testing results were in general 
very satisfactory, when omitting the relatively 
high number of deviations from expected 
results due to a change in the phenotype after 
passage in the meat matrices.   
 
6. References
EC 652/2013- COMMISSION IMPLEMENTING 
DECISION of 12 November 2013 on the 
monitoring and reporting of antimicrobial 
resistance in zoonotic and commensal bacteria. 
  
                                                                                                    
16 
7. Appendices
 
Appendix 1.  Pre-notification EURL-AR EQAS matrix 2017 
Appendix 2. List of participants 
Appendix 3. Expected results  
Appendix 3b  Deviating phenotype Sample M-3.4 
Appendix 4.  Protocol EQAS matrix 2017 
Appendix 5.  Examples of Test forms EQAS matrix 2017  
 
  
 
 
 
 
EURL-AR EQAS pre-notification 
G00-06-001/01.12.2014 
 
EQAS 2017 FOR SELECTIVE ISOLATION OF E. COLI WITH PRESUMPTIVE ESBL, 
AMPC PHENOTYPES OR CARBAPENEMASES FROM MEAT OR CAECAL SAMPLES 
The EURL-AR announces the launch of the third EQAS on matrix samples, providing the 
opportunity for proficiency testing which is considered an essential tool for the generation of 
reliable laboratory results of consistently good quality. 
This EQAS consists of testing of eight samples for selective isolation of ESBL, AmpC or 
carbapenemase-presumptive E. coli. 
This EQAS is specifically for NRL’s on antimicrobial resistance involved in the monitoring 
according to the EU Commission legislation 652/2013 and specifically processing meat and caecal 
samples in the specific monitoring for ESBL implemented in 2015. The laboratories designated to 
be NRL-AR will been contacted to confirm the addresses for the shipment of these samples. 
Participation is free of charge for all above-mentioned designated laboratories.  
TO AVOID DELAY IN SHIPPING THE ISOLATES TO YOUR LABORATORY 
The content of the parcel is categorized as “UN3373, Biological Substance Category B”. Eight 
samples which might contain ESBL, AmpC or carbapenemase-producing E. coli included in a 
matrix of meat and/or caecal will be shipped. Please provide the EQAS coordinator with documents 
or other information that can simplify customs procedures (e.g. specific text that should be written 
on the proforma invoice). To avoid delays, we kindly ask you to send this information already at 
this stage.  
TIMELINE FOR RESULTS TO BE RETURNED TO THE NATIONAL FOOD INSTITUTE 
Shipment of isolates and protocol: The isolates are expected to be shipped in the first week of 
November. The protocol for this proficiency test will soon be available for download from the 
website (http://eurl-ar.eu/208-eqas.htm)  
Submission of results: Results must be submitted to the National Food Institute no later than 
December, 18
th
, 2017 via a password-protected website. Upon reaching the deadline, each 
participating laboratory is kindly asked to enter the password-protected website once again to 
download an automatically generated evaluation report. 
EQAS report: A report summarising and comparing results from all participants will be issued. In 
the report, laboratories will be presented coded, which ensures full anonymity. The EURL-AR and 
the EU Commission, only, will have access to un-coded results. The report will be publicly 
available. 
 
Next EQAS: The next EURL-AR EQAS that we will have is on antimicrobial susceptibility testing 
of E. coli, staphylococci and enterococci which will be carried out in June, 2018.  
Please contact me if you have comments or questions regarding the EQAS. 
Sincerely, 
Jette Kjeldgaard 
Meat Caecal Institute  Country
x x Austrian Agency for Health and Food Safety Austria
x x Institute of Public Health Belgium
x x National Diagnostic and Research Veterinary Institute Bulgaria
x x Croatian Veterinary Institut Croatia
x x Veterinary Services Cyprus
x x State Veterinary Institute Praha Czech Republic
x x Danish Veterinary and Food Administration Denmark
x x Estonian Veterinary and Food Laboratory Estonia
x x Finnish Food Safety Authority EVIRA Finland
x x Agence nationale de sécurité sanitaire alimentation, environnement, travail France 
x x Federal Institute for Risk Assessment Germany
x x Veterinary Laboratory of Chalkida Greece
x x Central Agricultural Office Veterinary Diagnostic Directorate Hungary
x x Institute For Experimental Pathology, University of Iceland, KELDUR Iceland
x x Central Veterinary Research Laboratory Ireland
x x Istituto Zooprofilattico Sperimentale delle Regioni Lazio e Toscana Italy
x x Institute of Food Safety, Animal Health and Environment BIOR Latvia
x x National Food and Veterinary Risk Assessment Institute Lithuania
x x Laboratoire de Medecine Vétérinaire Luxembourg
x x Public Health Laboratory Malta
x x Wageningen Bioveterinary Research (WBVR) Netherlands
x x The Netherlands Food and Consumer Product Safety Authority* Netherlands
x x Veterinærinstituttet Norway
x x National Veterinary Research Institute Poland
x x Instituto Nacional de Investigação Agrária  e Veterinária Portugal
x Institute for Diagnosis and Animal Health Romania
x Institute for Hygiene and Veterinary Public Health Romania
x x State Veterinary and Food Institute  (SVFI) Slovakia 
x x National Veterinary Institute Slovenia
x Laboratorio Central de Veterinaria Spain
x Centro Nacional de Alimentación (AECOSAN) Spain
x x Foodborne Zoonoses and Antimicrobial Resistance Unit (ZTA)* Spain
x x National Veterinary Institute, SVA Sweden
x x Institute of Veterinary Bacteriology, Vetsuisse Faculty Bern Switzerland
x x Animal Plant Helath Agency United Kingdom
Designated NRL-AR by the compentent authority of the member state
Non-NRL-AR enrolled by the EURL-AR
Not a Member State of the EU
* Submitted results were not included in the current report (one dataset per country, only)
EURL strain Species MERO COL AMP AZI TAZ CHL CIP FOT GEN NAL SMX TET TMP TGC Genes ESBL conclusion 
Meat EURL-M-3.1 E. coli ≤0.03 ≤1 >64 >64 1 128 >8 >4 1 >128 >1024 >64 >32 ≤0.25 OXA-1/CTX-M-65 Presumptive ESBL
Meat EURL-M-3.2 E. coli Susceptible E. coli   -
Meat EURL-M-3.3 E. coli ≤0.03 ≤1 >64 4 4 ≤8 0.03 2 1 ≤4 16 ≤2 ≤0.25 ≤0.25 AmpC Presumptive AmpC
Meat EURL-M-3.4 E. coli 0.25 ≤1 >64 >64 ≤0.5 128 ≤0.015 ≤0.25 >32 ≤4 >1024 >64 >32 ≤0.25 OXA-48 (not ESBL)
Presumptive carbapanemase   
/OXA-48
Meat EURL-M-3.5 E. coli ≤0.03 ≤1 >64 >64 8 16 ≤0.015 >4 ≤0.5 ≤4 16 ≤2 ≤0.25 ≤0.25 TEM-1B Presumptive ESBL
Caecal EURL-M-3.6 E. coli ≤0.03 ≤1 >64 8 >8 >128 >8 >4 16 >128 >1024 >64 >32 ≤0.25 CTX-M-15 Presumptive ESBL
Caecal EURL-M-3.7 E. coli ≤0.03 ≤1 >64 8 >8 128 0.5 >4 ≤0.5 8 >1024 >64 0.5 ≤0.25 ESBL SHV12; TEM-1B Presumptive ESBL
Caecal EURL-M-3.8 Negative Negative   -
MIC interpretations
EURL strain Species MERO COL AMP AZI TAZ CHL CIP FOT GEN NAL SMX TET TMP TGC Phenotype
Meat EURL-M-3.1 E. coli S S R R R R R R S R R R R S ESBL
Meat EURL-M-3.2 E. coli Susceptible E. coli
Meat EURL-M-3.3 E. coli S S R S R S S R S S S S S S AmpC
Meat EURL-M-3.4 E. coli R S R R S R S S R S R R R S OXA-48 not ESBL
Meat EURL-M-3.5 E. coli S S R R R S S R S S S S S S ESBL
Caecal EURL-M-3.6 E. coli S S R S R R R R R R R R R S ESBL 
Caecal EURL-M-3.7 E. coli S S R S R R R R S S R R S S ESBL 
Caecal EURL-M-3.8 Negative Negative
Not tested - susceptible
Resistant
EURL strain Species FOX ETP IMI MERO TAZ FEP F/C T/C FOT TRM
Meat EURL-M-3.1 E. coli 4 ≤ 0.015 0.25 ≤ 0.03 1 2 ≤0.06/4 ≤0.12/4 64 4
Meat EURL-M-3.2 E. coli 
Meat EURL-M-3.3 E. coli 32 ≤ 0.015 0.25 ≤ 0.03 4 0.12 1/4 4/4 2 16
Meat EURL-M-3.4 E. coli 8 0.5 2 0.5 0.25 0.12 0.25/4 0.25/4 0.25 128
Meat EURL-M-3.5 E. coli 4 ≤ 0.015 ≤ 0.12 ≤ 0.03 8 32 ≤ 0.06/4 ≤ 0.12/4 >64 8
Caecal EURL-M-3.6 E. coli 8 0.03 ≤ 0.12 ≤ 0.03 32 32 0.12/4 0.25/4 64 16
Caecal EURL-M-3.7 E. coli 8 0.03 0.25 ≤ 0.03 32 0.5 ≤ 0.06/4 0.25/4 8 8
Caecal EURL-M-3.8 Negative
MIC interpretations
EURL strain Species FOX ETP IMI MERO TAZ FEP F/C T/C FOT TRM
Meat EURL-M-3.1 E. coli S S S S R R ≤0.06/4 ≤0.12/4 R S
Meat EURL-M-3.2 E. coli 
Meat EURL-M-3.3 E. coli R S S S R S 1/4 4/4 R S
Meat EURL-M-3.4 E. coli S R R R S S 0.25/4 0.25/4 S R
Meat EURL-M-3.5 E. coli S S S S R R ≤ 0.06/4 ≤ 0.12/4 R S
Caecal EURL-M-3.6 E. coli S S S S R R 0.12/4 0.25/4 R S
Caecal EURL-M-3.7 E. coli S S S S R R ≤ 0.06/4 0.25/4 R S
Caecal EURL-M-3.8 Negative
Not tested - susceptible
Resistant
Not applicable
Overview of deviating results in samples M-3.4 and M-3.5
EURL strain MERO COL AMP AZI TAZ CHL CIP FOT GEN NAL SMX TET TMP TGC
Meat EURL-M-3.4 0.25 ≤1 >64 8 ≤0.5 8 ≤0.015 0.5 - 2.0 0.5 ≤4 >1024 ≤2 0.25 ≤0.25
Meat EURL-M-3.5 ≤0.03 ≤1 >64 >64 8 16 8 >4 ≤0.5 >128 >1024 >64 >32 ≤0.25
EURL strain MERO COL AMP AZI TAZ CHL CIP FOT GEN NAL SMX TET TMP TGC
Meat EURL-M-3.4 R S R S S S S S/R R S R S S S
Meat EURL-M-3.5 S S R R R S R R S R R R R S
Resistant
EURL strain FOX ETP IMI MERO TAZ FEP F/C T/C FOT TRM
Meat EURL-M-3.4 8 0.5 0.25 - 0.5 0.5 0.25 0.25-1.0 0.25/4 0.25/4 0.5 - 2.0 128
Meat EURL-M-3.5 4 ≤ 0.015 ≤ 0.12 ≤ 0.03 8 32 ≤ 0.06/4 ≤ 0.12/4 >64 8
EURL strain FOX ETP IMI MERO TAZ FEP F/C T/C FOT TRM
Meat EURL-M-3.4 S R S R S R 0.25/4 0.25/4 R R
Meat EURL-M-3.5 S S S S R R ≤ 0.06/4 ≤ 0.12/4 R S
Resistant
Not applicable
Deviations marked in red
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1 INTRODUCTION 
The organisation and implementation of an External Quality Assurance System (EQAS) on 
selective isolation of presumptive extended spectrum beta-lactamase (ESBL)-, AmpC- or 
carbapenemase-producing E. coli is among the tasks of the EU Reference Laboratory for 
Antimicrobial Resistance (EURL-AR), and will include the selective isolation procedures and 
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antimicrobial susceptibility testing (AST) of obtained isolates of eight samples of either meat or 
caecal content. In 2017, these eight samples will include five 25-g samples of beef meat and three 
1-g samples of pig caecal content. These samples may contain E. coli presumptive of producing 
either ESBL-, AmpC- or carbapenemase-enzymes.  
It is expected that the participating laboratories apply the same analysis procedures used in the 
monitoring, described by the regulation EC/652/2013, and perform the selective isolation following 
the by EU recommended methods, published on the EURL-AR website www.eurl-ar.eu.  
2 OBJECTIVES 
This EQAS aims to assess and, if necessary, to improve the quality of results obtained in the 
selective isolation of presumptive ESBL-, AmpC- or carbapenemase-producing isolates from meat 
and caecal samples. Further objectives are to evaluate and improve the comparability of 
surveillance data on ESBL-, AmpC- or carbapenemase -producing E. coli reported to EFSA by 
different laboratories. 
3 OUTLINE OF THE EQAS 
3.1 Shipping, receipt and storage of samples 
In November 2017, the National Reference Laboratories for Antimicrobial Resistance (NRL-AR) 
will receive a parcel containing eight samples from the National Food Institute. All strains used in 
the spiking of samples belong to UN3373, Biological substance, category B. Participants should 
expect that ESBL-, AmpC- and/or carbapenemase-enzymes producing strains will be included in 
some of the sample matrices. 
The samples will be spiked matrices of either beef meat or pig caecal content and will be distributed 
already weighed and ready to be tested, in tubes labelled from 3.1 to 3.8. Hereof 3.1 to 3.5 being 
samples of meat (each 25 g) and 3.6 to 3.8 being samples of caecal content (each 1 g). 
The matrix samples will be shipped on November 6
th
 in frozen state in separate tubes and contained 
in a cooling box with a temperature logging devices and cooling elements.  
Upon arrival, it is very important to open the parcel as soon as possible and proceed to the analysis 
(following the normal procedures for sample testing in the monitoring).  
It is required that participants  
- when opening the parcel, note the date and exact time at opening (this data is very 
important to follow the temperature data checks) 
- proceed to sample analysis immediately after opening the parcel 
- register the date for start of analysis for each sample 
- collect the temperature logging device (small discoid device located in a bag inserted in 
a labelled tube, located inside the parcel); open the tube and take out the bag with the 
EU Reference Laboratory for Antimicrobial Resistance  
External Quality Assurance System (EQAS) 2017 
 
 
Page 3 of 9 
  
device inside. Place this bag with the device in the labelled bubble envelope provided and 
return it to the EURL-AR as soon as possible. Please note that you will have to arrange for 
stamps/postage (the post systems differ from country to country, why this cannot be 
arranged and paid from the EURL-AR in advance).  
 
3.2 Selective isolation of ESBL, AmpC or carbapenemase producing E. coli from the 
samples  
The samples provided in each parcel are weighed beforehand and therefore no further weighing is 
required. Proceed immediately to the first enrichment step by adding the sample to the necessary 
volume of media (225 ml of Buffered Peptone water for the meat samples and 9 ml for the caecal 
samples) as referred in the official EURL-AR protocols. All the following procedures should follow 
the methods used in the monitoring for ESBL and AmpC E. coli according to the EC/652/2013 
regulation. If any changes are introduced to the official protocols, these changes should be 
described with details in the online database on the methods upload page. The participants are 
responsible for assuring the validity of the plates and therefore the protocol for “Validation of 
selective MacConkey agar plates supplemented with 1 mg/L cefotaxime for monitoring of ESBL 
and AmpC producing E. coli in meat and animals” should be run beforehand, as stated on the 
EURL-AR webpage (see http://eurl-ar.eu/233-protocols.htm). 
Optionally, the participants may perform the additional plating for isolation of carbapenemase-
producing E. coli from the samples, following the official protocols and plating on suitable agar 
plates. Similarly, the agar plates used for the carbapenemase isolation should be validated using the 
protocol for “Validation of selective and indicative agar plates for monitoring of carbapenemase-
producing E. coli”. 
The officially recommended protocols are found on the EURL-AR webpage (http://eurl-ar.eu/233-
protocols.htm): 
 Follow the protocol for meat when testing samples 3.1 to 3.5 
 Follow the protocol for caecal content when testing samples 3.6 to 3.8 
As referred in these protocols, the isolates obtained from isolation procedure should be identified as 
E. coli using the procedures for E. coli species identification applied at the participant’s laboratory 
for the specific monitoring of ESBL- and AmpC-producing E.coli. 
Please store the isolates obtained in the isolation procedure and document the whole process as well 
as all the findings in each step.  
As part of the results submission, you will be requested to describe the findings along the 
enrichment process and selective isolation including growth in the media, isolation of suspected 
colonies, species identification results and finally regarding the finding (or not) of presumptive E. 
coli isolates harbouring one of the selected resistances (this result will be evaluated in relation to the 
expected result as a qualitative result) (see details in the Test Form).  
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3.3 Antimicrobial susceptibility testing 
If the sample is deemed positive for ESBL- , AmpC- or carbapenemase -producing E. coli, one E. 
coli isolate per sample should be taken further and tested for susceptibility to antimicrobials as 
stated in the EU regulation (antimicrobials listed in Tables 1 and 2 in this document).  
Only one E.coli isolate is expected to be tested for AST and these results will be evaluated in the 
database comparing to expected results.  
AST results to be reported should be from: 
 A presumptive carbapenemase positive isolate (from the CARBA or OXA-48 selective plates), 
if this optional part was performed and a presumptive carbapenemase positive E. coli isolate 
was detected.  
 An ESBL- or AmpC-presumptive isolate (if you do not have a carbapenemase positive isolate or 
if you did not perform the optional plating) if an ESBL- or AmpC-presumptive isolate was 
detected. 
 
The testing should be performed using the same method as implemented in your laboratory for 
performing AST when monitoring for EFSA according to the regulation EC/652/2013 (using the 
two-step approach, i.e. both testing panels) and applying the interpretative criteria listed below. 
 
Table 1. Antimicrobials recommended for AST of Escherichia coli and interpretative criteria 
according to table 1 in Commission Implementing Decision 2013/652/EU 
 
Antimicrobials for E. coli 
MIC (mg/L) 
R is > 
Ampicillin, AMP 8 
Azithromycin, AZI 16* 
Cefotaxime, FOT 0.25  
Ceftazidime, TAZ 0.5  
Chloramphenicol, CHL 16 
Ciprofloxacin, CIP 0.064  
Colistin, COL 2 
Gentamicin, GEN 2 
Meropenem, MERO 0.125 
Nalidixic acid, NAL 16 
Sulfamethoxazole, SMX 64 
Tetracycline, TET 8 
Tigecycline, TGC 0.5** 
Trimethoprim, TMP 2 
* Tentative ECOFF  
** EUCAST.org 
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Plasmid-mediated quinolone resistance  
When performing AST of E. coli, the interpretative criteria listed in Table 1 for results obtained by 
MIC-determination should allow detection of plasmid-mediated quinolone-resistant test strains.  
Beta-lactam resistance 
Confirmatory testing for ESBL production is mandatory on all strains resistant to cefotaxime 
(FOT), ceftazidime (TAZ) and/or meropenem (MERO) and should be performed by testing the 
second panel of antimicrobials (Table 2). 
 
 
Table 2. Antimicrobials recommended for additional AST of Escherichia coli resistant to 
cefotaxime, ceftazidime or meropenem and interpretative criteria according to Table 4 in 
Commission Implementing Decision 2013/652/EU. 
 
Antimicrobials for E. coli 
MIC (mg/L) 
R is > 
Cefepime, FEP 0.125 
Cefotaxime, FOT  0.25 
Cefotaxime + clavulanic acid (F/C) Not applicable 
Cefoxitin, FOX 8 
Ceftazidime, TAZ 0.5 
Ceftazidime+ clavulanic acid (T/C) Not applicable 
Ertapenem, ETP 0.06 
Imipenem, IMI 0.5 
Meropenem, MERO 0.125 
Temocillin, TRM >32* 
*Tentative ECOFF  
Confirmatory test for ESBL production requires use of both cefotaxime (FOT) and ceftazidime 
(TAZ) alone and in combination with a -lactamase inhibitor (clavulanic acid). Synergy is defined 
either as i) a ≥ 3 twofold concentration decrease in an MIC for either antimicrobial agent tested in 
combination with clavulanic acid vs. the MIC of the agent when tested alone (MIC FOT : FOT/CL 
or TAZ : TAZ/CL ratio  8) (CLSI M100 Table 3A, Tests for ESBLs). The presence of synergy 
indicates ESBL production.  
Confirmatory test for carbapenemase production requires the testing of meropenem (MERO).  
Detection of AmpC-type beta-lactamases can be performed by testing the bacterium for 
susceptibility to cefoxitin (FOX). Resistance to FOX could indicate the presence of an AmpC-type 
beta-lactamase. 
The classification of the phenotypic results should be based on the most recent EFSA 
recommendations (EURL-AR Workshop 2016, https://www.eurl-
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ar.eu/CustomerData/Files/Folders/3-workshop-kgs-lyngby-april2016/25_efsa-eusr-amr-workflow-
and-criteria-for-esbl-ampc-carbapenemase-phenotypes.pdf and in the appendix to this protocol). 
 
 
4 REPORTING OF RESULTS AND EVALUATION 
Please write your results in the test forms, and enter your results into the interactive web database.  
 
4.1 General recommendations for data upload 
We recommend reading carefully the description reported in paragraph 5 before entering your 
results in the web database. Results must be submitted no later than 18th, December, 2017. After 
the deadline when all participants have uploaded results, you will be able to login to the database 
once again, and to view and print an automatically generated report evaluating your results. Results 
in agreement with the expected interpretation are categorised as ‘correct’, while results deviating 
from the expected interpretation are categorised as ‘incorrect’. 
If you experience difficulties in entering your results, please contact us directly.  
All results will be summarized in a report which will be publicly available. The data in the report 
will be presented with laboratory codes. A laboratory code is known to the individual laboratory, 
whereas the complete list of laboratories and their codes is confidential and known only to the 
EURL-AR and the EU Commission. All conclusions will be public. 
If you have questions, please do not hesitate to contact the EQAS Coordinator: 
Jette Sejer Kjeldgaard 
National Food Institute 
Technical University of Denmark 
Kemitorvet, Building 204,  
DK-2800 Lyngby 
Denmark 
Tel: +45 3588 6269 
E-mail: jetk@food.dtu.dk 
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5 HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE 
Please read carefully this paragraph before entering the web page. 
Remember that you need by your side the completed test forms.  
Enter the EURL-AR EQAS 2017 start web page (http://eurl.food.dtu.dk/matrix ), write your 
username and password in lower-cases and press enter. Your username and password are indicated 
in the Welcome letter following the samples. Do not hesitate to contact us if you experience 
problems with the login. 
You can browse back and forth by using the Home or back keys, but please remember to save your 
inputs before. 
5.1 Sample reception/testing 
Please fill in with information in relation to date and time (please note the exact time) and 
temperature at arrival of the parcel contents as measured by you (we will also check on the thermo-
loggers data after you send back the device. 
5.2 Selective enrichment methods 
Please fill in with the details of the methods use and insert any changes made to the official method 
5.3 Test results  
 
5.3.1 Selective enrichment of presumptive ESBL- , AmpC- or carbapenemase -producing E. 
coli 
Fill in the answers for the questions regarding the selective enrichment results along the process 
 
5.3.2 Species identification enrichment of presumptive ESBL- or AmpC-producing E. coli 
Please confirm the results and conclude if you found an E. coli presumptive of producing an ESBL 
or AmpC gene in the sample (this conclusion will be evaluated). 
Please confirm the results and conclude also if you found an E. coli presumptive of producing a 
carbapenemase or OXA-type enzyme in the sample (these conclusions will be evaluated 
separately). 
If you respond to the above questions indicating that you did not find a presumptive isolate to go 
further you are not expected to fill in the remaining questions. 
If your answer is ‘yes’ for both or one of the above, you are expected to fill in the MIC tables and 
final conclusion of the AST and confirmatory testing. 
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5.3.3 AST of E. coli 
Based on the first MIC panel results, indicate if the isolate fulfils the criteria to be tested on the 
second panel (confirmatory phenotypic testing) or not, and fill in the results for the second panel in 
case you decide to do the confirmatory testing. 
Complete the fields in the result tables related to the results obtained. 
Click on “save” and then go back using the tab “home” and enter another test page to upload results  
In the data entry pages, enter the obtained values and the interpretation (R, resistant or S, 
susceptible) for each E. coli isolate. 
Remember to report also the conclusion of the phenotypic testing on the second panel (will be 
evaluated separately). 
If you did not test for susceptibility to a given antimicrobial, please leave the field empty. 
Click on “save“ and then go back using the tab “home” and enter another test page to upload 
results.  
Click on “save“. 
5.4 Finalizing data input, EQAS evaluation and approval of result upload 
Review the input pages by browsing through the pages and make corrections if necessary. 
Remember to save a page if you make corrections. If you press home a page without saving 
changes, you will see an error screen. In this case, click on “save“ to save your results, browse back 
to the page and then continue. 
Please complete the evaluation form for the EQAS when you finalize the data input. You can find 
the tab on the Home page, on the tab “Evaluation” 
Before approving your input, please be sure that you have filled in all the relevant fields for the 
sample sheet, the methods and the test results for all samples tested because YOU CAN ONLY 
APPROVE ONCE! The approval blocks your data entry in the interactive database. 
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APPENDIX 
 
Criteria for interpretation of Escherichia coli, panel 2 results 
 
 
 
 
 
Please refer to the presentation at https://www.eurl-ar.eu/CustomerData/Files/Folders/3-workshop-
kgs-lyngby-april2016/25_efsa-eusr-amr-workflow-and-criteria-for-esbl-ampc-carbapenemase-
phenotypes.pdf 
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Test forms, 
Isolation of ESBL/AmpC- and carbapenemase-producers from matrices 
 
 
Username:       
Contact person:                                
 
Country:       
Date for filling in test forms:            
 
 
 
 
SAMPLES 
 
Reception date and exact time of opening the parcel of the proficiency test samples at the 
laboratory:             (date and time is required) 
 
Temperature of the contents of the parcel at arrival:      °C 
 
 
How many samples did your laboratory process in 2017 for monitoring of ESBL/AmpC-detection in 
relation to 2013/652/EU? (choose only one option) 
 less than 100 
 101-200 
 201-300 
 301-400 
 401- 1000  
 more than 1000 
 
 
Which kind of samples did your laboratory process in 2017 for monitoring of ESBL/AmpC-
detection in relation to 2013/652/EU? (you may choose more than one option) 
  caecal, pig 
  meat, beef 
  other matrices, please specify:                      
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Did you process samples for carbapenemase-selective isolation?  
 Yes 
  No 
 
 
How many samples did your laboratory process in 2017 for monitoring of carbapenemases in 
relation to 2013/652/EU? (Choose only one option) 
 less than 100 
 101-200 
 201-300 
 301-400 
 401- 1000  
 more than 1000 
 
 
Which kind of samples did your laboratory process in 2017 for monitoring of carbapenemase-
production in relation to 2013/652/EU? (you may choose more than one option) 
  caecal, pig 
  meat, beef 
  other matrices, please specify:                      
 
Any other comments:                                                    
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METHODS 
                                                        
1- Method used for selective isolation of ESBL/AmpC  in this EQAS:  
 
Selective isolation procedure using the EURL recommended protocols that refer to the EU 
regulation 652/2013/EU  
 
 The protocol was used without modifications (please jump to question 2) 
 The protocol was used, however, the pre-enrichment was modified (please respond 
question 1.1) 
 The protocol was used, however, the selective isolation procedures were modified (please 
respond question 1.2) 
 The protocol was used, however, the incubation conditions in the selective plating were 
modified (please respond question 1.3) 
 
 
1.1- If you modified the pre-enrichment, please indicate the differences introduced: 
 
 Different sample amount (weight) used for the enrichment procedure:  
       g in meat samples 
       g for caecal samples 
  
 Different volume of enrichment in the isolation step:  
       ml for meat samples 
       ml for caecal samples 
  
 Different pre-enrichment medium:      
Different incubation conditions in pre-enrichment      °C/     h;  
  
 Please justify these changes:      
 
  
 1.2- If you made changes in the selective isolation procedure: 
 
 Different sample amount (weight) used for the enrichment procedure:  
       g in meat samples 
       g for caecal samples 
 
 Different concentration of cefotaxime:        mg/L      
 Different antimicrobial               
 Different medium       
     Please justify these changes:      
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1.3- If you used different incubation conditions in the selective plating, please indicate 
the conditions used:      °C/     h;  
   
 Please justify these changes:      
 
 
 
2- Method used for selective isolation of carbapenemase-producers (in case you run this 
method)  in this EQAS:  
 
Selective isolation procedure using the EURL recommended protocols for isolation of 
carbapenemase-producers: 
  We did not perform carbapenemase selective isolation 
  The protocol was used without modifications  
  The protocol was modified  
 
 Plates used (brand/type)       
 Please justify these changes:      
 
 
 
3- Method used for confirmation of E. coli species identification. Please indicate the primary 
E. coli identification method used (choose only one option; if you used more than one 
method, please explain in the comments field) 
 
 PCR using published methods 
 PCR using in-house method 
  Biochemical tests 
  MALDI-ToF  
  DNA Sequencing  
  Chromogenic media 
 
Comments:                                               
 
 
 
4- Method used for general antimicrobial susceptibility testing of the strains (choose only one 
option) 
 
 Microbroth dilution test on EUVSEC panel  
 Microbroth dilution test on another panel  
 Agar dilution method 
  E-test 
  Disk diffusion test 
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5- Method used for phenotypic confirmatory testing of ESBL/AmpC (choose only one option) 
 
 Microbroth dilution test on EUVSEC2 panel  
 Microbroth dilution test on another panel  
 Agar dilution method 
  E-test 
  Disk diffusion test 
 
 
 
6- Additional comments. Please include here description and justification of your choice if you 
modified something in relation to the method defined in the EU regulation 2013/652/EU: 
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TEST FORM – SAMPLE ‘EURL M-3.X’ 
Date the isolation procedure was started:   
Please describe the results you have observed regarding this sample: 
Visible growth in pre-enrichment: 
 Yes / No
Growth on ESBL/AmpC-selective plates: 
 Yes  / No 
Please describe the growth observed on ESBL/AmpC-selective plates? (choose only one 
option) 
 Mixed culture containing typical E. coli colonies 
 Mixed culture without typical E. coli colonies 
 Pure culture of typical E. coli colonies 
 Pure culture without typical E. coli colonies 
 No growth 
Results of species identification: (choose only one option) 
 No isolates tested (sample negative) 
 Presumptive ESBL/AmpC isolate identified as E. coli (sample considered positive) 
Comments:   
Did you perform carbapenemase selective plating? 
Yes  / No 
Growth on CARBA-selective plates: 
 Yes  / No 
Growth on OXA-48 selective plates: 
 Yes  / No 
Results of species identification (isolates from carbapenemase selective plating): (choose 
only one option) 
 No isolates tested (sample negative) 
 Presumptive other carbapenemase isolate identified as E. coli (sample considered positive) 
 Presumptive OXA-48 isolate identified as E. coli (sample considered positive) 
Comments: 
If you have found a presumptive carbapenemase positive isolate, please insert the results 
of antimicrobial susceptibility testing for the selected E. coli isolate, if you do not have a 
carbapenemase positive isolate and you have an ESBL presumptive isolate, please insert 
the results for this isolate (only one E.coli isolate is expected to be tested and these results 
will be evaluated in our database against the expected results). 
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Please confirm where the isolate tested for antimicrobial susceptibility originated from 
(compulsory): 
 ESBL/ampC isolation on MacConkey with cefotaxime  
 CARBA plate   
 OXA-48 plate  
Based on the results from the first AST panel, was the isolate found resistant to 
cefotaxime, ceftazidime or meropenem so that the second panel was tested? 
Yes  /  No 
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AST results  
Strain Antimicrobial Results and interpretation 
 
> 
MIC-value (mg/L) S / R 
E. coli EURL  
M-3.X
Ampicillin, AMP      
Azithromycin, AZI 
Cefotaxime, FOT 
Ceftazidime, TAZ 
Chloramphenicol, CHL 
Ciprofloxacin CIP     
Colistin, COL 
Gentamicin, GEN 
Meropenem, MERO 
Nalidixic acid, NAL 
Sulfamethoxazole, SMX 
Tetracycline, TET 
Tigecycline, TGC 
Trimethoprim, TMP 
Second E. coli AST panel (confirmatory testing for ESBL/AmpC/carbapenemase-production)
Strain Antimicrobial Results and interpretation 
 
> 
MIC-value (mg/L) S / R 
E. coli 
EURL M-3.X
Cefepime, FEP 
Cefotaxime + clavulanic acid (F/C) 
Cefotaxime, FOT 
Cefoxitin, FOX 
Ceftazidime, TAZ 
Ceftazidime+ clavulanic acid (T/C) 
Ertapenem, ETP 
Imipenem, IMI 
Meropenem, MERO 
Temocillin, TRM 
Conclusions of confirmatory phenotypic testing: (choose only one option and please note that the final 
result will be evaluated by the database) 
Interpretation of PANEL 2 results: 
 Presumptive ESBL 
 Presumptive ESBL+ AmpC 
 Presumptive AmpC 
 Presumptive carbapenemase 
 Other phenotype 
 Susceptible 
Comments (include optional genotype or other results): 
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